Page last updated: 2024-12-04

clofibric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Clofibric acid is a fibric acid derivative that acts as a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It is used in the treatment of hyperlipidemia, specifically to lower triglyceride levels and raise high-density lipoprotein (HDL) cholesterol levels. Clofibric acid is synthesized through various chemical processes, often involving the reaction of a phenol derivative with an appropriate acid chloride or anhydride. Its mechanism of action involves binding to and activating PPARα, leading to increased expression of genes involved in lipid metabolism, such as lipoprotein lipase, which hydrolyzes triglycerides in the blood. Clofibric acid has been shown to exhibit beneficial effects on cardiovascular health by lowering triglycerides and raising HDL cholesterol, but it also carries risks, including potential liver toxicity and an increased risk of gallstones. Despite its therapeutic potential, clofibric acid has been associated with adverse effects and is not widely used in many countries. Extensive research has been conducted on clofibric acid to explore its therapeutic potential, investigate its mechanisms of action, and evaluate its safety profile. These studies have contributed to our understanding of lipid metabolism, PPARα signaling, and the development of new drugs for lipid disorders.'

Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2797
CHEMBL ID683
CHEBI ID34648
SCHEMBL ID102826
MeSH IDM0004584

Synonyms (187)

Synonym
AC-15616
4-chlorophenoxy-iso-butyrcc acid
53pf01q249 ,
alpha-(4-(chlorphenoxy)-2-methylpropionsaeure
unii-53pf01q249
ccris 9254
MLS002153998
HMS3266H12
2-(4-chloro-phenoxy)-2-methyl-propionic acid
BB 0244890
BRD-K19111024-001-05-0
KBIO1_000226
DIVK1C_000226
clofibrinsaeure
alpha-(4-chlorophenoxy)-alpha-methylpropionic acid
CHEBI:34648 ,
acidum clofibricum
acido clofibrico
alpha-(p-chlorophenoxy)isobutyric acid
acide (p-chlorophenoxy)-2 methyl-2 propionique
acide clofibrique
SPECTRUM_000160
acidum chlorphibricum
nsc 1149
acide clofibrique [inn-french]
brn 1874067
acido clofibrico [inn-spanish]
4-(chlorophenoxy)isobutyric acid (van)
clofibrinsaeure [german]
clofibric acid [inn:dcf]
einecs 212-925-9
acidum clofibricum [inn-latin]
acide (p-chlorophenoxy)-2 methyl-2 propionique [french]
p-chlorophenoxyisobutyric acid
PRESTWICK_39
cas-882-09-7
tocris-0825
NCGC00016547-01
NCGC00024807-01
IDI1_000226
BSPBIO_002051
D07723
MLS001183705
smr000677911
clofibric acid (inn)
SPECTRUM5_001985
BPBIO1_000976
PRESTWICK2_000783
PRESTWICK3_000783
AB00051950
bdbm28699
chembl683 ,
propionic acid, 2-(p-chlorophenoxy)-2-methyl-
chlorfibrinic acid
regulipid
clofibric acid
(p-chlorophenoxy)isobutyric acid
p-(2,4-chlorophenoxy)isobutyric acid
2-(p-chlorophenoxy)isobutyric acid
(chlorophenoxy)isobutyric acid
4-(chlorophenoxy)isobutyric acid
nsc-1149
clofibrin
pcib
.alpha.-(4-chlorophenoxy)isobutyric acid
4-cpib
propanoic acid, 2-(4-chlorophenoxy)-2-methyl-
2-(p-chlorophenoxy)-2-methylpropionic acid
acetic acid, (p-chlorophenoxy)dimethyl-
nsc1149
pcpib
2-(4-chlorophenoxy)-2-methylpropionic acid
2-(4-chlorophenoxy)-2-methylpropanoic acid
regadrin
clofibrinic acid
clofibrate free acid
chlorofibrinic acid
882-09-7
.alpha.-(4-chlorophenoxy)-.alpha.-methylpropionic acid
.alpha.-(p-chlorophenoxy)isobutyric acid
chlorophibrinic acid
SR-01000597447-2
2-(p-chlorophenoxy)-2-methylpropionic acid, 97%
NCGC00024807-03
NCGC00024807-05
NCGC00024807-04
NCGC00024807-02
KBIOSS_000640
KBIO2_005776
KBIO2_003208
KBIO3_001271
KBIO2_000640
KBIOGR_000846
SPECTRUM4_000293
PRESTWICK0_000783
SPBIO_000294
NINDS_000226
SPBIO_002825
SPECTRUM2_000157
SPECTRUM3_000356
PRESTWICK1_000783
SPECTRUM1500195
SPECTRUM5_001569
BSPBIO_000886
STK141126
MLS001336024
MLS001336023
2-(4-chlorophenoxy)isobutyric acid
AKOS000109304
HMS500L08
FT-0665115
HMS1570M08
HMS1920O17
NCGC00016547-06
2-(4-chlorophenoxy)-2-methylpropionic acid;clofibric acid
A842499
HMS2097M08
tox21_301680
dtxcid9020661
NCGC00255701-01
dtxsid1040661 ,
BBL009445
nsc-756697
pharmakon1600-01500195
nsc756697
tox21_110486
2-(p-chlorophenoxy)-2-methyl-propionic acid
HMS2236F05
S4207
CCG-38959
NCGC00016547-03
NCGC00016547-05
NCGC00016547-04
NCGC00016547-02
FT-0623988
clofibric acid [who-dd]
clofibric acid [mi]
clofibric acid [inn]
HMS3373E14
2-(p-chlorophenoxy) isobutyric acid
p-chloro phenoxy isobutyric acid
2-(4-chlorophenoxy)-2-methyl-propionic acid
2-methyl-2-(4-chlorophenoxy)propionic acid
2-(p-chlorophenoxy)-2-methylpropanoic acid
2-(p-chloro-phenoxy)-2-methyl-propionic acid
p-chlorophenoxy-2-methylpropionic acid
2-(4-chloro-phenoxy)-2-methyl-propionic acid
SCHEMBL102826
NCGC00016547-08
tox21_110486_1
HS-0042
CS-4700
W-100413
4-chlorophenoxy isobutyric acid
AS-871/13465032
propanoic acid, 2-methyl, 2-(4-chlorophenyloxy)
HY-B1415
AC-31448
AB00051950_08
AB00051950_09
mfcd00004192
clofibric acid, analytical reference material
SR-01000597447-1
SR-01000597447-5
sr-01000597447
SR-01000597447-6
HMS3652B13
2-(4-chlorophenoxy)-2-methylpropionic acid 10 microg/ml in acetonitrile
SBI-0051317.P002
HMS3714M08
SW196355-3
Q3080279
F16050
HMS3675N07
BCP13968
HMS3411N07
BRD-K19111024-001-17-5
BRD-K19111024-001-10-0
A16463
clofibric-acid
2-(4-chloranylphenoxy)-2-methyl-propanoic acid
e0o ,
NCGC00016547-09
EN300-18267
2-(4-chlorophenoxy)-2-methylpropanoicacid
2-(4-chlorophenoxy)-2-methylpropionic acid 100 microg/ml in acetonitrile
Z57727844

Research Excerpts

Overview

Clofibric acid (CLO) is a nongenotoxic hepatocarcinogen in rodents that causes altered hepatocellular foci and/or neoplasms. Clofibrate (CA) is an active metabolite of the blood lipid lowering agent clofibrates.

ExcerptReferenceRelevance
"Clofibric acid (CA) is an active metabolite of the blood lipid lowering agent clofibrate, a pharmaceutical designed to work as agonist of peroxisome proliferator-activated receptor alpha (PPARa). "( Chronic effects of clofibric acid in zebrafish (Danio rerio): a multigenerational study.
André, A; Capitão, A; Carvalho, AP; Castro, LF; Coelho, I; Coimbra, AM; Gesto, M; Lacerda, R; Lima, D; Lyssimachou, A; Peixoto, MJ; Santos, MM; Soares, J, 2015
)
2.19
"Clofibric acid (CLO) is a peroxisome proliferator (PP) that acts through the peroxisome proliferator activated receptor alpha, leading to hepatocarcinogenesis in rodents. "( Liver gene expression profiles of rats treated with clofibric acid: comparison of whole liver and laser capture microdissected liver.
Boitier, E; Desdouets, C; Gautier, JC; Michel, C; Roberts, R; Sacre-Salem, B, 2003
)
2.01
"Clofibric acid (CL) is a compound used to control hypertriglyceridemia, and ethacrynic acid (ET) is administered to enhance diuresis. "( Aryloxoalcanoic compounds induce resistance to antibiotic therapy in urinary tract infection caused by Escherichia coli.
Balagué, C; De Duffard, AM; De Ruiz, CS; Duffard, R; Nader-Macías, ME; Rey, R; Stürtz, N, 2006
)
1.78
"Clofibric acid (CLO) is a nongenotoxic hepatocarcinogen in rodents that causes altered hepatocellular foci and/or neoplasms. "( Diethylnitrosamine initiation does not alter clofibric acid-induced hepatocarcinogenesis in the rat.
Boitier, E; Desdouets, C; Isaacs, KR; Michel, C; Roberts, RA; Slaoui, M, 2007
)
2.04

Effects

Clofibric acid has a futile cycle in which its net clearance is dependent upon conjugation to form an acyl (ester) glucuronide. It has a less pronounced effect on warfarin binding than does phenylbutazone or tolbutamide.

ExcerptReferenceRelevance
"Clofibric acid has a less pronounced effect on warfarin binding than does phenylbutazone or tolbutamide."( Effects of phenylbutazone, tolbutamide, and clofibric acid on binding of racemic warfarin and its enantiomers to human serum albumin.
Kapoor, A; Veronich, K; White, G, 1979
)
1.24
"Clofibric acid has been shown previously to undergo a futile cycle in which its net clearance is dependent upon conjugation to form an acyl (ester) glucuronide and a combination of hydrolysis of the conjugate and its renal clearance. "( Diisopropylfluorophosphate increases clofibric acid clearance: supporting evidence for a futile cycle.
Meffin, PJ; Rowe, BJ, 1984
)
1.98
"Clofibric acid alone has only marginal effects on the myeloid differentiation, whereas clofibric acid together with the glucocorticoid analogue dexamethasone gives a larger effect."( Potentiating effects of clofibric acid on the differentiation of HL-60 human promyelocytic leukemia cells induced by retinoids.
Farrants, AK; Finstad, HS; Nesland, JM; Nilsson, A; Pedersen, JI, 1995
)
1.32
"Clofibric acid has a less pronounced effect on warfarin binding than does phenylbutazone or tolbutamide."( Effects of phenylbutazone, tolbutamide, and clofibric acid on binding of racemic warfarin and its enantiomers to human serum albumin.
Kapoor, A; Veronich, K; White, G, 1979
)
1.24

Treatment

Treatment with clofibric acid markedly increased the hepatic exposure of 2-PPA-CoA by 2.9-fold and led to a 25% increase (p < 0.05) in covalent binding of 2 PPA to liver protein. Treatment with clfibric Acid did not change the concentration of octadecenoic acid in brain, lung, heart, spleen, testis and adipose tissue.

ExcerptReferenceRelevance
"3. Clofibric acid treatment increased markedly the activities of FAD-glycerol-3-P dehydrogenase, beta-hydroxyacyl-CoA dehydrogenase, cytochrome-c oxidase, malic enzyme, NAD-glycerol-3-P dehydrogenase, ethoxycoumarin deethylase, p-nitroanisole demethylase and amounts of cytochrome P-450 and b5."( Cetaben is an exceptional type of peroxisome proliferator.
Chandoga, J; Hampl, L; Hocman, G; Rojeková, I; Turecký, L; Uhliková, E, 1994
)
0.8
"Clofibric acid treatment caused an increase in both the 51-kDa CYP2 protein as well as in liver somatic index."( Immunochemical characterization of hepatic cytochrome P450 isozymes in the channel catfish: assessment of sexual, developmental and treatment-related effects.
Perkins, EJ; Schlenk, D, 1998
)
1.02
"Treatment with clofibric acid markedly increased the hepatic exposure of 2-PPA-CoA by 2.9-fold and led to a 25% increase (p < 0.05) in covalent binding of 2-PPA to liver protein."( Differential effects of fibrates on the metabolic activation of 2-phenylpropionic acid in rats.
Badagnani, I; Benet, LZ; Fife, KL; Grillo, MP; Li, C, 2008
)
0.69
"Treatment with clofibric acid did not change the concentration of octadecenoic acid in brain, lung, heart, spleen, testis and adipose tissue."( Induction of microsomal stearoyl-CoA desaturase by the administration of various phenoxyacetic acid derivatives.
Hanioka, N; Kawashima, Y; Kozuka, H, 1984
)
0.61
"Pretreatment with clofibric acid or spironolactone resulted in a significant increase in the biliary excretion of the phenolic glucuronide."( Glucuronidation and elimination of diflunisal in the isolated perfused rat liver: effect of pretreatment with phenobarbitone, clofibric acid and spironolactone.
Dobbs, BR; Faed, EM; Lee, D, 1984
)
0.8
"Treatment with clofibric acid increased the activity of 1-acyl-GPC acyltransferase in liver of mouse as well as rat, but did not change the activity in liver of guinea-pig."( Selective increase in acylation of 1-acylglycerophosphorylcholine in livers of rats and mice by peroxisome proliferators.
Hirose, A; Kawashima, Y; Kozuka, H, 1984
)
0.61
"Treatment with clofibric acid over a long period of time may well give rise to additional reactions through influences exerted upon the insulin level."( [Effect of clofibric acid on fatty acid metabolism in HLP patients in the 2d half of life].
Reuter, W, 1982
)
0.99

Toxicity

ExcerptReferenceRelevance
"5%), three abandoned because of gastrointestinal adverse effects, six other patients also complaint of gastrointestinal side effects."( [Safety of ciprofibrate. Open study in a Portuguese population].
Branco, MC; de Moura, JP; Ferraz, A; Ferreira, MR; Jesus, LC; Pereira, M; Serra e Silva, P; Silva, JM, 1995
)
0.29
" Safety was assessed from reports of adverse events and by measuring haematological and biochemical parameters."( Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia.
Betteridge, DJ; O'Bryan-Tear, CG, 1996
)
0.29
" Physical and laboratory investigations for adverse effects were performed every month for the first 3 months and every 3 months thereafter."( Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
Athyros, VG; Carina, MV; Didangelos, TP; Hatzikonstandinou, HA; Kontopoulos, AG; Kranitsas, DF; Papageorgiou, AA, 1997
)
0.3
" However, the evidence for reducing CHD risk by raising HDL-C is thin, predominantly due to the paucity of effective and safe HDL-increasing drugs."( Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
Birjmohun, RS; Hutten, BA; Kastelein, JJ; Stroes, ES, 2005
)
0.33
"A systematic review of cohort studies, randomized trials, voluntary notifications to national regulatory authorities, and published case reports was undertaken to assess the incidence and characteristics of adverse effects in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins."( Statin safety: a systematic review.
Law, M; Rudnicka, AR, 2006
)
0.33
" Myopathy, liver enzyme elevations, and cholecystitis have been potential adverse reactions of interest."( Expert commentary: the safety of fibrates in lipid-lowering therapy.
Brown, WV, 2007
)
0.34
" Safety evaluations (adverse events, laboratory parameters) did not reveal any clinically significant adverse effects of etofibrate in comparison to placebo."( [Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy].
Emmerich, KH; Erbler, H; Goldsteine, J; Görtelmeyer, R; Klindzane, M; Poritis, N; Stelmane, I, 2009
)
0.35
"Etofibrate provides a safe and effective treatment for ocular pathology resulting from type 2 diabetes mellitus."( [Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy].
Emmerich, KH; Erbler, H; Goldsteine, J; Görtelmeyer, R; Klindzane, M; Poritis, N; Stelmane, I, 2009
)
0.35
" The toxicity of the oxidation products obtained during the reaction was assessed by means of Vibrio fischeri and Daphnia magna tests in order to evaluate the potential formation of toxic by-products."( Identification of intermediates and assessment of ecotoxicity in the oxidation products generated during the ozonation of clofibric acid.
Boltes, K; García-Calvo, E; Gonzalo, MS; Letón, P; Rosal, R; Vaquero, JJ, 2009
)
0.56
" Due to the adverse effects provoked by hypolipidemic drugs on skeletal muscle function, we also investigated the blocking activity of S-2 and S-4 on skeletal muscle membrane chloride channel conductance and found that these ligands have a pharmacological profile more beneficial compared to fibrates currently used in therapy."( New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function.
Conte Camerino, D; Fracchiolla, G; Laghezza, A; Lavecchia, A; Loiodice, F; Mazza, F; Montanari, R; Novellino, E; Piemontese, L; Pierno, S; Pochetti, G; Tortorella, P, 2009
)
0.35
" This work provides an insight into non-covalent interactions between emerging contaminants and biomolecule, and is helpful for clarifying the toxic mechanism of such emerging contaminants."( Interactions of acidic pharmaceuticals with human serum albumin: insights into the molecular toxicity of emerging pollutants.
Chen, J; Gao, H; Qian, Y; Zhang, Y; Zhou, X, 2012
)
0.38

Pharmacokinetics

ExcerptReferenceRelevance
" After oral administration of single daily doses for 7 days, the plasma elimination half-life for bezafibrate was rapid (t1/2 of 4-5 h) in comparison to ciprofibrate (t1/2 of 76 h)."( The comparative pharmacokinetics and gastric toxicity of bezafibrate and ciprofibrate in the rat.
Bonner, FW; Eason, CT; Henry, G; Pattison, A; Powles, P; Spencer, AJ, 1989
)
0.28
" A mechanistic scheme for the degradation of plafibride is proposed, which agrees with the observed pharmacological and pharmacokinetic data."( Pharmacokinetic approach of plafibride in rat.
Bruseghini, L; Ribalta, JM; Torres, A; Vilageliu, J; Zapatero, D, 1981
)
0.26
"Bezafibrate is a new lipid-lowering agent with a more pronounced pharmacological effect, a different metabolism and a much shorter apparent half-life than clofibrate."( Comparative pharmacokinetics of 400 mg bezafibrate after a single oral administration of a new slow-release preparation and the currently available commercial form.
Kaufmann, B; Ledermann, H, 1981
)
0.26
" Serum concentrations of both CFB and clofibric acid (CFA) were measured by HPLC and the pharmacokinetic analysis was made by a non-compartmental method."( [Pharmacokinetics of clofibrate in jaundiced newborn infants at term].
Bourget, P; Broise, I; Gabilan, JC; Quinquis-Desmaris, V, 1995
)
0.56
" Pharmacokinetic profiles were similar in both groups of infants."( [Pharmacokinetics of clofibrate in jaundiced newborn infants at term].
Bourget, P; Broise, I; Gabilan, JC; Quinquis-Desmaris, V, 1995
)
0.29
" Recently conducted metabolic and pharmacokinetic drug-drug interaction studies using gemfibrozil or fenofibrate in combination with five commonly used statins demonstrated a widely different drug interaction potential for these two fibrates."( Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
Davidson, MH, 2006
)
0.33

Compound-Compound Interactions

ExcerptReferenceRelevance
"Fibric acid derivatives may interact with other drugs and the interactions can be of clinical relevance."( Drug interactions with fibric acids.
Dujovne, CA; Lozada, A, 1994
)
0.29
" Fibrates also have the potential to cause rhabdomyolysis, although generally only in combination with HMG-CoA reductase inhibitors, and are subject to binding by concomitantly administered bile acid sequestrants."( Antihyperlipidaemic agents. Drug interactions of clinical significance.
Farmer, JA; Gotto, AM, 1994
)
0.29
" Since antiaggregation treatment with acetylsalicylic acid is a complex part of obligatory therapy of these patients, the authors studied the influence of ciprofibrate on chosen lipid parameters, fibrinogen and thromboxane in monotherapy, and also in combination with acetylsalicylic acid (ASA) in patients with advanced atherosclerosis and hyperlipoproteinemia."( [The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia].
Cibulova, L; Fedelesova, V; Gajdos, M; Huttova, D; Krivosikova, Z; Mongiellova, V; Polak, F, 1999
)
0.3
" Although the National Cholesterol Education Programme Adult Treatment Panel III guidelines recommend the use of fibrates in combination with statins in patients at very high risk of CHD (e."( Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
Davidson, MH, 2006
)
0.33
" This may at least partially explain the lower incidence of myopathy with fenofibrate compared with gemfibrozil when combined with statins."( Fibrates in combination with statins in the management of dyslipidemia.
Jacobson, TA; Zimmerman, FH, 2006
)
0.33
" In the present study, we examined the mRNA levels of peroxisome proliferator- and estrogen-sensitive genes on the exposure of primary rainbow trout (Oncorhynchus mykiss) hepatocytes to CA alone and in combination with the natural female sex hormone, 17β-estradiol (E2)."( Effects of clofibric acid alone and in combination with 17β-estradiol on mRNA abundance in primary hepatocytes isolated from rainbow trout.
Liedtke, A; Schirmer, K; Sovadinová, I, 2014
)
0.79

Bioavailability

The bioavailability of these moieties in etofibrate was compared to that from equimolar amounts of these drugs administered alone to rhesus monkeys. We investigated the bioavailability and persistence of the human PPARα ligand clofibric acid (CFA) in carp, together with various relevant endpoints.

ExcerptReferenceRelevance
" The bioavailability of these moieties in etofibrate was compared to that from equimolar amounts of these drugs administered alone to rhesus monkeys (clofibric acid 354 mg, nicotinic acid 203 mg)."( Bioavailability studies of etofibrate in rhesus monkeys.
Chasseaud, LF; Schatton, W; Taylor, T; Waller, AR, 1985
)
0.47
"The relative bioavailability of 2-(p-chlorophenoxy)-2-methylpropionic acid [2-(nicotinyloxy)-ethyl]-ester (etofibrate) from Lipo-Merz retard (500 mg) with respect to Lipo-Merz (600 mg) has been determined in 10 health volunteers in a crossover study."( Relative bioavailability of etofibrate. A comparison of an acute and a new sustained release formulation.
Hoppe, HJ; Johnson, KI; Schatton, W, 1984
)
0.27
" Bile acid sequestrants are the most difficult of these agents to administer concomitantly, because their nonspecific binding results in decreased bioavailability of a number of other drugs, including thiazide diuretics, digitalis preparations, beta-blockers, coumarin anticoagulants, thyroid hormones, fibric acid derivatives and certain oral antihyperglycaemia agents."( Antihyperlipidaemic agents. Drug interactions of clinical significance.
Farmer, JA; Gotto, AM, 1994
)
0.29
" Endothelial dysfunction and a reduced generation or bioavailability of NO have emerged as major pathophysiological mechanisms in ED."( Dyslipidemia as a risk factor for erectile dysfunction.
Mikhailidis, DP; Paraskevas, KI; Vrentzos, GE, 2007
)
0.34
" We investigated the bioavailability and persistence of the human PPARα ligand clofibric acid (CFA) in carp, together with various relevant endpoints, at a concentration similar to therapeutic levels in humans (20mg/L) and for an environmentally relevant concentration (4μg/L)."( Effects of the lipid regulating drug clofibric acid on PPARα-regulated gene transcript levels in common carp (Cyprinus carpio) at pharmacological and environmental exposure levels.
Corcoran, J; Cumming, R; Lange, A; Owen, SF; Tyler, CR; Winter, MJ, 2015
)
0.92
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The dose-response for ibuprofen and flurbiprofen was roughly equivalent to that of clofibric acid, whereas indomethacin was less active. After treatment for 7 days reductions in cholesterol were similar at all dosages of ciprofibrate.

ExcerptRelevanceReference
" Clofibrate required a dosage of 180 mg/kg to suppress the tyloxapol effect."( Metabolic effects of a new hypolipidemic agent, ciprofibrate.
Arnold, A; Beyler, AL; McAuliff, MP, 1979
)
0.26
" Dose-response curves in which the block of GCl by the S-(-) isomer was evaluated in the presence of the R-(+) isomer (3-10 microM) clearly showed an antagonistic interaction between the two enantiomers, with an increase in the S-(-) concentration for half-maximal block."( Opposite effects of enantiomers of clofibric acid derivative on rat skeletal muscle chloride conductance: antagonism studies and theoretical modeling of two different receptor site interactions.
Bryant, SH; Conte Camerino, D; De Luca, A; Tortorella, V; Tricarico, D; Wagner, R, 1992
)
0.56
" These findings represent the first report assessing the in-vivo interaction potential of structurally similar and dissimilar peroxisome proliferators and provides insight into the dose-response nature of joint exposures to certain non-genotoxic carcinogens."( Effects of joint exposures to selected peroxisome proliferators on hepatic acyl-CoA oxidase activity in male B6C3F1 mice.
Baldwin, LA; Calabrese, EJ; Leonard, DA; Ochs, JB, 1992
)
0.28
"The dose-response for key hepatic effects of the peroxisome proliferator ciprofibrate, 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2- methylpropanoic acid, was delineated in mice and strain differences in response were demonstrated."( Dose-response relationships of hepatic acyl-CoA oxidase and catalase activity and liver mitogenesis induced by the peroxisome proliferator ciprofibrate in C57BL/6N and BALB/c mice.
Angeloff, K; Budroe, JD; Umemura, T; Williams, GM, 1992
)
0.28
" The effects of different dosing regimens of three hypolipidaemic, peroxisome-proliferator drugs on hepatic enzymes in the Fischer rat following 26 weeks treatment have been studied."( Hepatic induction potency of hypolipidaemic drugs in the rat following long-term administration: influence of different dosing regimens.
Bonner, FW; Gibson, GG; Makowska, JM, 1990
)
0.28
" It is concluded that, from a pharmacokinetic point of view, a reduction in the dosage of ciprofibrate should be considered in patients with a glomerular filtration rate below 30 ml min-1/1."( The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate.
Bernard, N; Cuisinaud, G; Ferry, N; Gardes, E; Labeeuw, M; Pozet, N; Sassard, J; Zech, PY, 1989
)
0.28
" The profiles of isoenzymes induced in vitro were compared with those induced in liver microsomes of rats dosed with the same agents."( Induction of cytochrome P-450 in cultured rat hepatocytes. The heterogeneous localization of specific isoenzymes using immunocytochemistry.
Bars, RG; Elcombe, CR; Mitchell, AM; Wolf, CR, 1989
)
0.28
" Radioactivity was rapidly taken up by the liver and to a lesser extent by the brown fat within 9 h after oral dosing of ciprofibrate."( In vivo distribution of a carcinogenic hepatic peroxisome proliferator: whole-body autoradiography of [14C]ciprofibrate in the mouse.
Marlowe, C; Rao, MS; Reddy, JK; Waddell, WJ, 1989
)
0.28
"2-fold) but not clofibrate or bezafibrate when dosed PO at 50 mg/kg for 2 weeks in cholesterol-fed rats."( Gemfibrozil increases both apo A-I and apo E concentrations. Comparison to other lipid regulators in cholesterol-fed rats.
Krause, BR; Newton, RS, 1986
)
0.27
"As a basis for establishing dosing guidelines in order to avoid side effects due to overdosage, the concentrations of total and free non-protein bound clofibrinic acid (CA) were determined before and after the administration of a single clofibrate dose (0, 2, 6, 12, 24, 48, 72, 96h) in patients with various degrees of impaired renal function and in a control group (n = 56)."( Serum levels of free non-protein bound clofibrinic acid after single dosing to patients with impaired renal function of various degrees--a multicenter study.
Graben, N; Hartmann, H; Merk, W; Nikolaus, C; Schlierf, G; Schwandt, P, 1987
)
0.27
" The study, followed-up as an open trial using higher doses (100 or 200 mg/day ciprofibrate, 400 mg/day fenofibrate) tried to demonstrate clearly the benefit of therapy after 9 months with the 2 drugs and to establish the dose-response effects."( Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B.
Bakir, R; Chanu, B; Djian, F; Goy-Loeper, J; Rouffy, J, 1985
)
0.27
"2-[4(2,2- Dichlorocyclopropyl )phenoxy]2-methyl propionic acid (ciprofibrate), a peroxisome proliferator , induced hepatocytes in the pancreas of adult male F-344 rats when added to their diet at a dosage of 10 mg/kg body weight for 60-72 wk."( Induction and origin of hepatocytes in rat pancreas.
Lalwani, ND; Qureshi, SA; Rao, MS; Reddy, JK; Reddy, MK; Scarpelli, DG, 1984
)
0.27
" The drug was administered at four dosage levels during induction of arteriosclerosis in order to establish a possible dose-effect relationship."( Hypolipemic profile of plafibride in a model of experimental atherosclerosis.
Badimón, JJ; Cánovas, M; Padró, T; Vidal, M; Villaverde, CA, 1983
)
0.27
" With a dosage of 200 mg daily the effects were maintained for the following period of 6 months."( Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
Olsson, AG; Orö, L, 1982
)
0.26
" Since the apparent volumes of distribution were in the same range for both drugs, the amount of drug present in the organism in steady-state also differed by a factor of approximately 30 under the usual dosage regimen."( Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers.
Abshagen, U; Marinow, J; Spörl-Radun, S, 1980
)
0.26
" Adequate dosage in RDT patients was found to be 200mg every 3rd day."( Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
Grützmacher, P; Lang, W; Scheuermann, E, 1981
)
0.26
" An individualized dosage of bezafibrate and repeated checks of the serum concentrations of the drug are recommended during long-term treatment of uremic patients."( Treatment of uremic hypertriglyceridaemia with bezafibrate.
Anderson, P; Norbeck, HE, 1982
)
0.26
" Thus, when treating hyperlipoproteinaemia in patients with impaired renal function, the dosage of bezafibrate must be individualized because of its reduced renal elimination."( Clinical pharmacokinetics of bezafibrate in patients with impaired renal function.
Anderson, P; Norbeck, HE, 1981
)
0.26
" Lipo-Merz retard was administered in a dosage of one capsule/day, the combination product in a dosage of one capsule three times daily."( [Therapy of lipoproteinemia. Comparison between Lipo-Merz retard and a commercial combination drug].
Steger, W, 1980
)
0.26
"In a randomised blind study with 404 patients 1 capsule Etofibrate per day (500 mg) in sustained release dosage form was tested in comparison to other lipid-lowering drugs."( [An alternative in the therapy of primary hyperlipemias: etofibrate in depot preparations].
Füsgen, I; Summa, JD, 1980
)
0.26
" Therefore, rats were dosed with 0, 50 or 300 mg/kg of clofibric acid for 4 days by gavage, and the livers were examined by immunocytochemistry."( Induction of cytochrome P450 and peroxisomal enzymes by clofibric acid in vivo and in vitro.
Bars, RG; Bell, DR; Elcombe, CR, 1993
)
0.78
" The data obtained in the dose-response study of cetaben revealed a significant rise in the activities of peroxisomal enzymes in both the liver and kidney at doses of 50-100 mg/kg body wt administered over 10 days, but the maximal effect was observed at 250 mg/kg."( Cetaben and fibrates both influence the activities of peroxisomal enzymes in different ways.
Chandoga, J; Hampl, L; Hocman, G; Rojeková, I, 1994
)
0.29
" Male and female marmosets were dosed with ciprofibrate (2, 10, and 20 mg/kg) by oral gavage once daily for 3 years."( Lack of peroxisome proliferation in marmoset liver following treatment with ciprofibrate for 3 years.
Bonner, FW; Graham, MJ; Old, SL; Rees, JA; Spencer, AJ; Wilson, SA; Winham, MA, 1994
)
0.29
" The dose-response for ibuprofen and flurbiprofen was roughly equivalent to that of clofibric acid, whereas indomethacin was less active."( Induction of peroxisomal beta-oxidation by nonsteroidal anti-inflammatory drugs.
Eacho, PI; Foxworthy, PS; Perry, DN, 1993
)
0.51
" The results provide support for a unified receptor-based mechanism controlling the main PP response, but demonstrate that individual responsive genes can show quite different dose-response curves."( The effects of peroxisome proliferators on protein abundances in mouse liver.
Anderson, NL; Eacho, P; Esquer-Blasco, R; Foxworthy, P; Richardson, F, 1996
)
0.29
" In this study, we compared the extent and pattern of covalent adduct formation in plasma and livers of rats dosed with the nonsteroidal anti-inflammatory drugs (NSAIDs) zomepirac (ZP) and diflunisal (DF), the hypolipidemic agent clofibric acid (CA), and the anti-epileptic agent valproic acid (VPA)."( Chemical and immunochemical comparison of protein adduct formation of four carboxylate drugs in rat liver and plasma.
Bailey, MJ; Dickinson, RG,
)
0.31
" After treatment for 7 days reductions in cholesterol were similar at all dosages of ciprofibrate (45% reduction, mean across groups) whereas the effects of WIN 36117, clofibric acid and fluorofibric acid were still dosage related (reductions of 21-44, 37-43 and 2-28% respectively)."( Comparative hypolipidaemic and peroxisomal effects of ciprofibrate, clofibric acid, and their respective difluorocyclopropyl and 4-fluoro-substituted analogues in rat.
Graham, MJ; Gray, TJ; Old, SL; Winham, MA, 1996
)
0.72
"Omeprazole dosing increased serum gastrin 4-fold, ciprofibrate 5-fold, and the combination 24-fold."( Potentiating hypergastrinemic effect by the peroxisome proliferator ciprofibrate and omeprazole in the rat.
Hammer, TA; Sandvik, AK; Waldum, HL, 1998
)
0.3
" Typically four rats are dosed for 4 days using oral doses in the range 50-500 mg kg(-1) day(-1)."( Rapid determination of rat hepatocyte mRNA induction potential using oligonucleotide probes for CYP1A1, 1A2, 3A and 4A1.
Evans, DC; Heavens, R; Jack, A; Meneses-Lorente, G; Surry, DD, 2000
)
0.31
" Female Fischer rats were dosed with ciprofibrate (50 mg/kg body weight per day) alone or combined with octreotide LAR (10 mg/30 days) for 60 days."( Octreotide inhibits the enterochromaffin-like cell but not peroxisome proliferator-induced hypergastrinemia.
Bakke, I; Sandvik, AK; Waldum, HL, 2000
)
0.31
" We performed in vitro studies incubating CA-SG with gamma-GT to determine the products formed, and in vivo studies examining the products excreted in urine after dosing rats with CA-SG or CA."( Interaction of gamma-glutamyltranspeptidase with clofibryl-S-acyl-glutathione in vitro and in vivo in rat.
Benet, LZ; Grillo, MP, 2001
)
0.31
" Gastrin probably plays an important role in gastric tumorgenesis, and long-term dosing with ciprofibrate results in enterochromaffin-like (ECL) cell carcinoids in the oxyntic mucosa of rats."( Antral G cells in rats during dosing with a PPAR alpha agonist: a morphometric and immunocytochemical study.
Bendheim, MØ; Martinsen, TC; Skogaker, NE; Waldum, HL, 2003
)
0.32
" The 60-day dosing period was chosen to elucidate both the metabolic and proliferative actions of this substance, while avoiding confounding effects from the hepatic carcinogenesis seen during more long-term stimulation."( Liver gene expression in rats in response to the peroxisome proliferator-activated receptor-alpha agonist ciprofibrate.
Bakke, I; Komorowski, J; Kusnierczyk, W; Laegreid, A; Sandvik, AK; Waldum, HL; Yadetie, F, 2003
)
0.32
" All groups were dosed at a constant 2 ml/kgBW volume of PEIB in the DEP vehicle at concentrations calculated to administer 0, 100, 300 or 1000 mg PEIB/kgBW/day."( Evaluation of the dermal subchronic toxicity of phenoxyethyl isobutyrate in the rat.
Api, AM, 2004
)
0.32
" This article (1) discusses the mechanisms of action of antilipidemic medications, (2) reviews dosing regimens and the pharmacokinetic differences among drugs of the same class, (3) assesses risk for drug interactions, and (4) reviews the clinical trial evidence used to support the use of particular antilipidemic medications in specific physiologic settings."( Comparative effects of lipid-lowering therapies.
Davidson, MH; Toth, PP,
)
0.13
" Comparing animals dosed with vehicle only, PPAR-alpha KO mice had higher serum gastrin concentration than WT mice."( Ciprofibrate stimulates the gastrin-producing cell by acting luminally on antral PPAR-alpha.
Aamo, T; Bakke, I; Chen, D; Martinsen, TC; Sandvik, AK; Waldum, HL; Zahlsen, K, 2005
)
0.33
"Testicular and adrenal steroidogenic enzymes were measured radiometrically following oral dosing of rats with ciprofibrate (2-[4-(2,2-dichlorocyclopropyl) phenoxyl]-2-methylpropinoic acid), a peroxisome proliferator."( Effects of ciprofibrate on testicular and adrenal steroidogenic enzymes in the rat.
Cooke, GM; Curran, IH; Hierlihy, AM; Karamanos, L; Mehta, R; Price, CA, 2006
)
0.33
" Statistically significant increases in mean fluorescence intensity were observed from animals dosed at 30, 150, and 400 mg/kg/day compared to control."( Flow cytometric assessment of peroxisome proliferation from frozen liver of fibrate-treated monkeys.
Cariello, NF; Colton, HM; Creech, DR; Falls, JG; Kwanyuen, P; Witherspoon, SM,
)
0.13
" This article summarises the mechanisms of action of available lipid lowering agents, their recommended dosing regiments and possible drug interactions."( [Treatment of dyslipidemia in clinical practice].
Harangi, M; Paragh, G, 2006
)
0.33
"4%) achieved goal following treatment changes, including upward dosage adjustments."( Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study.
Márk, L; Ofner, P; Pados, G; Paragh, G; Zámolyi, K, 2007
)
0.34
" Alderley Park and 129S4/SvJae mice dosed with methylclofenapate induced hepatocyte DNA synthesis at 4, but not 2, days after dosing and proved that inconsistency with prior work was not due to a difference in mouse strain or PPARalpha ligand."( Species-specific kinetics and zonation of hepatic DNA synthesis induced by ligands of PPARalpha.
Al Kholaifi, A; Amer, A; Bell, DR; Gray, TJ; Jeffery, B; Roberts, RA, 2008
)
0.35
" The CBZ removal efficiency was enhanced with the increase of RSB dosage without pH control."( Biosorption of clofibric acid and carbamazepine in aqueous solution by agricultural waste rice straw.
Chen, X; Dai, C; Liu, Z; Zhang, J; Zhang, Y; Zhou, X, 2013
)
0.74
" Applying extensions of a hormetic dose-response model that is well-established in plant biology provides a direct estimation of several quantities, except the hormetic dose range."( Statistical modeling of the hormetic dose zone and the toxic potency completes the quantitative description of hormetic dose responses.
Belz, RG; Piepho, HP, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
anticholesteremic drugA substance used to lower plasma cholesterol levels.
antilipemic drugA substance used to treat hyperlipidemia (an excess of lipids in the blood).
PPARalpha agonistA PPAR modulator which activates the peroxisome proliferator-activated receptor-alpha.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
marine xenobiotic metaboliteAny metabolite produced by metabolism of a xenobiotic compound in marine macro- and microorganisms.
herbicideA substance used to destroy plant pests.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (40)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency0.63100.044717.8581100.0000AID485294
USP1 protein, partialHomo sapiens (human)Potency39.81070.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency6.51310.000811.382244.6684AID686978
Microtubule-associated protein tauHomo sapiens (human)Potency44.66840.180013.557439.8107AID1460
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency19.43300.000214.376460.0339AID588532; AID720691
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency28.18380.001024.504861.6448AID588535
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency5.01190.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency0.79430.00255.840031.6228AID899
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency3.98110.010039.53711,122.0200AID588547
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency25.11890.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fatty acid-binding protein, intestinalHomo sapiens (human)Ki17.70000.30005.48149.4000AID1801103
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor ionotropic, NMDA 2DHomo sapiens (human)EC50 (µMol)300.00000.02101.27372.8000AID156801
Glutamate receptor ionotropic, NMDA 3BHomo sapiens (human)EC50 (µMol)300.00000.02100.51051.0000AID156801
Peroxisome proliferator-activated receptor alphaMus musculus (house mouse)EC50 (µMol)33.68070.00021.397110.0000AID156231; AID156453; AID240162
Peroxisome proliferator-activated receptor gammaHomo sapiens (human)EC50 (µMol)221.33330.00000.992210.0000AID156801; AID1798916; AID240268
Peroxisome proliferator-activated receptor gammaMus musculus (house mouse)EC50 (µMol)450.00000.00031.654210.0000AID157279; AID157283
Peroxisome proliferator-activated receptor deltaHomo sapiens (human)EC50 (µMol)55.00000.00020.84609.1000AID1798916
Glutamate receptor ionotropic, NMDA 1Homo sapiens (human)EC50 (µMol)300.00000.02100.35851.0000AID156801
Neuronal acetylcholine receptor subunit alpha-7Rattus norvegicus (Norway rat)EC50 (µMol)0.04200.00021.848110.0000AID240162
Peroxisome proliferator-activated receptor alphaHomo sapiens (human)EC50 (µMol)52.17780.00061.607410.0000AID156123; AID1633574; AID1798916; AID240267; AID438409; AID439613; AID609349; AID693448; AID718853
Glutamate receptor ionotropic, NMDA 2AHomo sapiens (human)EC50 (µMol)300.00000.02100.32421.0000AID156801
Glutamate receptor ionotropic, NMDA 2BHomo sapiens (human)EC50 (µMol)300.00000.02100.51701.0000AID156801
Glutamate receptor ionotropic, NMDA 2CHomo sapiens (human)EC50 (µMol)300.00000.02101.24032.7000AID156801
Glutamate receptor ionotropic, NMDA 3AHomo sapiens (human)EC50 (µMol)300.00000.02100.51051.0000AID156801
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (196)

Processvia Protein(s)Taxonomy
startle responseGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
adult locomotory behaviorGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of sensory perception of painGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
cellular response to L-glutamateGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
long-term synaptic potentiationGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
protein insertion into membraneGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
regulation of calcium ion transportGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
calcium ion transmembrane transportGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
fatty acid metabolic processFatty acid-binding protein, intestinalHomo sapiens (human)
long-chain fatty acid transportFatty acid-binding protein, intestinalHomo sapiens (human)
intestinal lipid absorptionFatty acid-binding protein, intestinalHomo sapiens (human)
fatty acid transportFatty acid-binding protein, intestinalHomo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of cholesterol effluxPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
long-chain fatty acid transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of osteoblast differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of receptor signaling pathway via STATPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of low-density lipoprotein receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of MAP kinase activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adiponectin secretionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cardiac muscle hypertrophy in response to stressPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of connective tissue replacement involved in inflammatory response wound healingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
placenta developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
G protein-coupled receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of blood pressurePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of lipid storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of angiogenesisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
monocyte differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
epithelial cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to lipidPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peroxisome proliferator activated receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
glucose homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
mRNA transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipoprotein transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of blood vessel endothelial cell migrationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
innate immune responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell fate commitmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
retinoic acid receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell maturationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
rhythmic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
white fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of SMAD protein signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cholesterol transporter activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to low-density lipoprotein particle stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to hypoxiaPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of mitochondrial fissionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of extracellular matrix assemblyPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cellular response to transforming growth factor beta stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adipose tissue developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular associated smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular endothelial cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
glucose metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
generation of precursor metabolites and energyPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
lipid metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fatty acid beta-oxidationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
apoptotic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
embryo implantationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cholesterol metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cell population proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
axon ensheathmentPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fatty acid catabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
regulation of skeletal muscle satellite cell proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fatty acid transportPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
intracellular receptor signaling pathwayPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cell-substrate adhesionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cellular response to nutrient levelsPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
wound healingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
steroid hormone mediated signaling pathwayPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of skeletal muscle tissue regenerationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
keratinocyte proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of fat cell differentiationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of myoblast differentiationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
decidualizationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of epithelial cell proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
keratinocyte migrationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
adipose tissue developmentPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fat cell proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of fat cell proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cellular response to hypoxiaPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
energy homeostasisPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
apoptotic signaling pathwayPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
glucose transmembrane transportPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of myoblast proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor deltaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cellular response to amyloid-betaGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
monoatomic cation transportGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
visual learningGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of calcium ion transport into cytosolGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
propylene metabolic processGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
regulation of membrane potentialGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
response to ethanolGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
protein heterotetramerizationGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium ion homeostasisGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of reactive oxygen species biosynthetic processGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
response to glycineGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
negative regulation of cytokine production involved in inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of reactive oxygen species biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of hepatocyte apoptotic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of ATP biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transformation of host cell by virusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to hypoxiaPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
heart developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
epidermis developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to starvationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of cellular ketone metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
intracellular receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid beta-oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of appetitePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to insulinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
circadian regulation of gene expressionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
behavioral response to nicotinePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
wound healingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipoprotein metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
steroid hormone mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to ethanolPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of blood pressurePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of glycolytic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nitric oxide metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of lipid biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
enamel mineralizationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to fructose stimulusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of leukocyte cell-cell adhesionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid transportPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to amyloid-betaGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
startle responseGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
response to amphetamineGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
learning or memoryGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
memoryGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
visual learningGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
response to xenobiotic stimulusGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
response to woundingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
sensory perception of painGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
neurogenesisGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
protein catabolic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
sleepGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
directional locomotionGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
negative regulation of protein catabolic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
dopamine metabolic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
serotonin metabolic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
positive regulation of apoptotic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
response to ethanolGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
activation of cysteine-type endopeptidase activityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
protein localization to postsynaptic membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
long-term synaptic potentiationGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
learning or memoryGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
response to ethanolGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
protein heterotetramerizationGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
negative regulation of dendritic spine maintenanceGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
long-term synaptic potentiationGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
response to woundingGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
directional locomotionGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
negative regulation of protein catabolic processGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
neuromuscular process controlling balanceGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
protein localization to postsynaptic membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
long-term synaptic potentiationGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
calcium ion transportGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
dendrite developmentGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
response to ethanolGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
rhythmic processGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
prepulse inhibitionGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
negative regulation of dendritic spine developmentGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
calcium ion transmembrane transportGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (63)

Processvia Protein(s)Taxonomy
glutamate-gated receptor activityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
glutamate bindingGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
voltage-gated monoatomic cation channel activityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
calcium channel activityGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
monoatomic cation channel activityGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
glycine bindingGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
neurotransmitter receptor activityGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
glutamate receptor activityGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
long-chain fatty acid transmembrane transporter activityFatty acid-binding protein, intestinalHomo sapiens (human)
fatty acid bindingFatty acid-binding protein, intestinalHomo sapiens (human)
protein bindingFatty acid-binding protein, intestinalHomo sapiens (human)
long-chain fatty acid bindingFatty acid-binding protein, intestinalHomo sapiens (human)
transcription cis-regulatory region bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
transcription coregulator bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
double-stranded DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
prostaglandin receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
enzyme bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peptide bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
identical protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear retinoid X receptor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
arachidonic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA binding domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
LBD domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
alpha-actinin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
R-SMAD bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
E-box bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
STAT family protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
transcription coactivator bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
nuclear steroid receptor activityPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
lipid bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
linoleic acid bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
sequence-specific double-stranded DNA bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium channel activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
amyloid-beta bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium ion bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calmodulin bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
glycine bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
glutamate bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
protein-containing complex bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
signaling receptor activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
ligand-gated monoatomic ion channel activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
transcription coactivator bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear steroid receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipid bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
phosphatase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein domain specific bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
mitogen-activated protein kinase kinase kinase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
ubiquitin conjugating enzyme bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein-containing complex bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
NFAT protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
MDM2/MDM4 family protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
amyloid-beta bindingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
zinc ion bindingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
amyloid-beta bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
zinc ion bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
glycine bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
glutamate bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
calcium channel activityGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
glycine bindingGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
identical protein bindingGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
protein phosphatase 2A bindingGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
glutamate receptor activityGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (37)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
presynaptic active zone membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
hippocampal mossy fiber to CA3 synapseGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
glutamatergic synapseGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
neuronal cell bodyGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
cytosolFatty acid-binding protein, intestinalHomo sapiens (human)
microvillusFatty acid-binding protein, intestinalHomo sapiens (human)
apical cortexFatty acid-binding protein, intestinalHomo sapiens (human)
cytosolFatty acid-binding protein, intestinalHomo sapiens (human)
nucleusFatty acid-binding protein, intestinalHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
nucleoplasmPeroxisome proliferator-activated receptor alphaMus musculus (house mouse)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cytosolPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
intracellular membrane-bounded organellePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II transcription regulator complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
receptor complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor gammaMus musculus (house mouse)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
nucleusPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cytoplasmGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synaptic vesicleGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
cell surfaceGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
postsynaptic densityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
dendriteGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
neuron projectionGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synaptic cleftGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
terminal boutonGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
dendritic spineGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synapseGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
excitatory synapseGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synaptic membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synapseGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
neuron projectionGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
synaptic vesicleGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
cell surfaceGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
postsynaptic densityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
cytoplasmic vesicle membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
presynaptic membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
dendritic spineGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
synaptic membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
glutamatergic synapseGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
cytoplasmGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
lysosomeGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
late endosomeGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
cytoskeletonGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
cell surfaceGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
postsynaptic densityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
neuron projectionGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
synaptic membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
glutamatergic synapseGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
membraneGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
neuron projectionGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
neuronal cell bodyGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
synapseGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
presynapseGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
glutamatergic synapseGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (143)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID243394Efficacy against murine PPARalpha relative to Wy-14,6432005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.
AID196199Serum cholesterol level in male Sprague-Dawley rats (fed with high cholesterol semisynthetic diet) after 7 days of treatment1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Dissociation of hypolipidemic and antiplatelet actions from adverse myotonic effects of clofibric acid related enantiomers.
AID240267Effective concentration against human PPARalpha expressed in HepG2 cells2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.
AID22149Solubility ratio ([HbS+drug (5 mM)]/[HbS-drug])1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
AID157279Compound was tested for its agonist activity against murine Peroxisome proliferator activated receptor gamma-Gal4 chimeric receptor in transfected CV-1 cells1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.
AID157283In vitro transcriptional activation of Peroxisome proliferator activated receptor gamma (PPAR) expressed in CV-1 cells1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones.
AID92840Compound was tested for the inhibitory activity against serotonin secretion by arachidonic acid (AA (0.1-1 mM)).1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Comparative antiaggregatory activity in human platelets of a benzopyranone aci-reductone, clofibric acid, and a 2,3-dihydrobenzofuran analogue.
AID156241In vitro transcriptional activation of peroxisome proliferator activated delta-receptor (PPAR) expressed in CV-1 cells; Inactive1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones.
AID718850Transactivation of human GAL4-fused PPARgamma ligand binding domain transfected in HEK293 cells after 18 hrs by dual luciferase reporter gene assay2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Synthesis and structure-activity relationships of fibrate-based analogues inside PPARs.
AID243395Efficacy against human PPARalpha expressed in HepG2 cells relative to Wy-14,6432005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.
AID440655Inhibition of CIC1 in Wistar rat extensor digitorum longus muscle assessed as decrease in resting chloride channel conductance at 100 uM by electrophysiology method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function.
AID718853Transactivation of human GAL4-fused PPARalpha ligand binding domain transfected in HEK293 cells after 18 hrs by dual luciferase reporter gene assay2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Synthesis and structure-activity relationships of fibrate-based analogues inside PPARs.
AID225587Inhibition against platelet aggregation induced by adenosine diphosphate (ADP) in vitro1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Dissociation of hypolipidemic and antiplatelet actions from adverse myotonic effects of clofibric acid related enantiomers.
AID225588Inhibition against platelet aggregation induced by arachidonic acid(AA) in vitro1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Dissociation of hypolipidemic and antiplatelet actions from adverse myotonic effects of clofibric acid related enantiomers.
AID1576358Permeability coefficient of compound in buffer containing 5% DMSO and 100 mM KCl at pH 6.8 incubated for 5 hrs by HDM-PAMPA based spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID1221782Cytotoxicity against HEK293 cells expressing UGT assessed as decrease in cell viability at 1 mM measured up to 72 hrs by MTT assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID196198Serum cholesterol level in male Sprague-Dawley rats (fed with high cholesterol semisynthetic diet) after 4 days of treatment.1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Dissociation of hypolipidemic and antiplatelet actions from adverse myotonic effects of clofibric acid related enantiomers.
AID693446Transactivation of PPARalpha expressed in HEK293A cells co-expressing GAL4 at 150 uM after 16 to 18 hrs by luciferase reporter gene assay relative to control2012European journal of medicinal chemistry, Dec, Volume: 58Fibrate-derived N-(methylsulfonyl)amides with antagonistic properties on PPARα.
AID438410Agonist activity at PPARalpha in human HepG2 cells assessed as increase in CPT1A mRNA expression at 150 uM after 48 hrs by RTqPCR relative to untreated control2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Synthesis and biological evaluation of 2-heteroarylthioalkanoic acid analogues of clofibric acid as peroxisome proliferator-activated receptor alpha agonists.
AID92835Compound was tested for the inhibitory activity against human platelet aggregation by arachidonic acid (AA (0.1-1 mM)).1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Comparative antiaggregatory activity in human platelets of a benzopyranone aci-reductone, clofibric acid, and a 2,3-dihydrobenzofuran analogue.
AID1576348Permeability coefficient of compound in phosphate buffer containing 5% DMSO at pH 7.4 incubated for 7 hrs by HDC/NOPE PAMPA based spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID21143Solubility of Deoxyhemoglobin S (dHbS) concentration after addition dithionite as control1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
AID1576350Thermodynamic solubility of compound in buffer containing HCl/KCl with 1% v/v DMSO at pH 1.2 incubated for 24 hrs by spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID439611Antagonist activity at mouse T1R2/T1R3 receptor expressed in HEK293E cells assessed as inhibition of sucralose-induced intracellular calcium mobilization2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Phenoxy herbicides and fibrates potently inhibit the human chemosensory receptor subunit T1R3.
AID22148Solubility ratio ([HbS+drug (40 mM)]/[HbS-drug])1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
AID240268Effective concentration against human PPARgamma expressed in HepG2 cells2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.
AID1576352Thermodynamic solubility of compound in buffer containing KH2PO4/Na2HPO4 with 1% v/v DMSO at pH 7.4 incubated for 24 hrs by spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID749046Inhibition of full-length human 11beta-HSD1 expressed in HEK293 cells at 10 uM after 2 hrs by scintillation proximity assay relative to control2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
Discovery, synthesis and in combo studies of a tetrazole analogue of clofibric acid as a potent hypoglycemic agent.
AID1576354Apparent solubility of compound in fed state simulated intestinal fluid at pH 5 by spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID243396Efficacy against human PPARgamma expressed in HepG2 cells relative to rosiglitazone2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.
AID156801Compound was tested for agonist activity on human Peroxisome proliferator activated receptor gamma-Gal4 chimeric receptor in transfected CV-1 cells1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.
AID240162Effective concentration against murine PPARalpha in transactivation assay2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.
AID21145Solubility of Haemoglobin S (HbS) concentration after addition of acid and dithionite1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
AID196200Serum cholesterol level in male Sprague-Dawley rats (fed with high cholesterol semisynthetic diet)before the treatment.1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Dissociation of hypolipidemic and antiplatelet actions from adverse myotonic effects of clofibric acid related enantiomers.
AID749042Hypoglycemic activity in STZ-nicotinamide-induced Wistar rat diabetic model after 1 to 7 hrs2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
Discovery, synthesis and in combo studies of a tetrazole analogue of clofibric acid as a potent hypoglycemic agent.
AID1576355Kinetic solubility of compound in HDM-PAMPA with buffer containing 5% DMSO at pH 1.2 incubated for 5 hrs by spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID326600Agonist activity at mouse PPARalpha receptor in monkey COS7 cells assessed as activation of CAT reporter gene at 300 uM by transactivation assay relative to Wy,14-6432008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Stereospecific synthesis and bio-activity of novel beta(3)-adrenoceptor agonists and inverse agonists.
AID439612Antagonist activity at human T1R2/T1R3 receptor expressed in HEK293E cells assessed as inhibition of sucralose-induced intracellular calcium mobilization2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Phenoxy herbicides and fibrates potently inhibit the human chemosensory receptor subunit T1R3.
AID1576359Permeability coefficient of compound in buffer containing 5% DMSO and 100 mM KCl at pH 7.4 incubated for 5 hrs by HDM-PAMPA based spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID91214Antigelling activity expressed as ratio of soluble sickle hemoglobin (HbS) of compound (g/dL) and that of control at 5 mM concentration.1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Design, synthesis, and testing of potential antisickling agents. 10. (2,2-Dimethylchroman-6-yl)alkanoic acids.
AID91209Antigelling activity expressed as ratio of soluble sickle hemoglobin (HbS) of compound (g/dL) and that of control at 20 mM concentration1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Design, synthesis, and testing of potential antisickling agents. 10. (2,2-Dimethylchroman-6-yl)alkanoic acids.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID439613Activity at PPARalpha2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Phenoxy herbicides and fibrates potently inhibit the human chemosensory receptor subunit T1R3.
AID438407Agonist activity at human PPARalpha expressed in HEK293 cells assessed as receptor transactivation at 150 uM by luciferase reporter gene assay relative to control2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Synthesis and biological evaluation of 2-heteroarylthioalkanoic acid analogues of clofibric acid as peroxisome proliferator-activated receptor alpha agonists.
AID438409Agonist activity at human PPARalpha expressed in HEK293 cells assessed as receptor transactivation at by luciferase reporter gene assay2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Synthesis and biological evaluation of 2-heteroarylthioalkanoic acid analogues of clofibric acid as peroxisome proliferator-activated receptor alpha agonists.
AID1307966Inhibition of human recombinant COX1 expressed in Sf9 cell microsomes assessed as reduction in conversion of arachidonic acid to PGE2 at 250 uM incubated for 5 mins by HTRF assay2016Journal of medicinal chemistry, 05-12, Volume: 59, Issue:9
Impact of Binding Site Comparisons on Medicinal Chemistry and Rational Molecular Design.
AID156123Compound was tested for agonist activity on human Peroxisome proliferator activated receptor alpha-Gal4 chimeric receptor in transfected CV-1 cells1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.
AID609349Agonist activity at PPARalpha ligand binding domain expressed in HEK293 cells co-expressing GAL4 after 18 hrs by dual-luciferase activity based transactivation assay2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Benzothiazole-based N-(phenylsulfonyl)amides as a novel family of PPARα antagonists.
AID92233Inhibition of U-46,619 induced human platelet aggregation1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Synthetic aci-reductones: 3,4-dihydroxy-2H-1-benzopyran-2-ones and their cis- and trans-4a,5,6,7,8,8a-hexahydro diastereomers. Antiaggregatory, antilipidemic, and redox properties compared to those of the 4-substituted 2-hydroxytetronic acids.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID624619Specific activity of expressed human recombinant UGT2B72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1576360Permeability coefficient of compound in phosphate buffer containing 0.5% DMSO at pH 7.4 incubated for 18 hrs by PAMPA-BBB assay based spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID92239Inhibition of arachidonic acid (AA) induced human platelet aggregation1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Synthetic aci-reductones: 3,4-dihydroxy-2H-1-benzopyran-2-ones and their cis- and trans-4a,5,6,7,8,8a-hexahydro diastereomers. Antiaggregatory, antilipidemic, and redox properties compared to those of the 4-substituted 2-hydroxytetronic acids.
AID92237Inhibition of adenosine diphosphate (ADP) induced serotonin secretion1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Synthetic aci-reductones: 3,4-dihydroxy-2H-1-benzopyran-2-ones and their cis- and trans-4a,5,6,7,8,8a-hexahydro diastereomers. Antiaggregatory, antilipidemic, and redox properties compared to those of the 4-substituted 2-hydroxytetronic acids.
AID92234Inhibition of U-46,619 induced serotonin secretion1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Synthetic aci-reductones: 3,4-dihydroxy-2H-1-benzopyran-2-ones and their cis- and trans-4a,5,6,7,8,8a-hexahydro diastereomers. Antiaggregatory, antilipidemic, and redox properties compared to those of the 4-substituted 2-hydroxytetronic acids.
AID326598Agonist activity at mouse PPARalpha receptor in monkey COS7 cells assessed as activation of CAT reporter gene at 50 uM by transactivation assay relative to Wy,14-6432008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Stereospecific synthesis and bio-activity of novel beta(3)-adrenoceptor agonists and inverse agonists.
AID1576357Kinetic solubility of compound in HDM-PAMPA with buffer containing 5% DMSO at pH 7.4 incubated for 5 hrs by spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID185030Minimum effective dose producing a 40-60% decrease in serum TLDL cholesterol in rats relative to vehicle -treated controls; ND = Not determined1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.
AID1576356Kinetic solubility of compound in HDM-PAMPA with buffer containing 5% DMSO at pH 6.8 incubated for 5 hrs by spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID22013Solubility ratio ([HbS+drug (20 mM)]/[HbS-drug]1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
AID179410Concentration to block chloride membrane conductance (G Cl) in rat extensor digitorum longus (EDL) muscle fibers (in vivo and in vitro)1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Stereospecificity of the chloride ion channel: the action of chiral clofibric acid analogues.
AID1633574Transactivation of GAL4-tagged human PPARalpha LBD expressed in human HepG2 cells at 100 nM to 100 uM incubated for 20 to 22 hrs by luciferase reporter gene assay2019ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4
Novel Phenyldiazenyl Fibrate Analogues as PPAR α/γ/δ Pan-Agonists for the Amelioration of Metabolic Syndrome.
AID193998Liver cholesterol level in male Sprague-Dawley rats (fed with high cholesterol semisynthetic diet) after 1 week of treatment.1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Dissociation of hypolipidemic and antiplatelet actions from adverse myotonic effects of clofibric acid related enantiomers.
AID693448Transactivation of PPARalpha expressed in HEK293A cells co-expressing GAL4 after 16 to 18 hrs by luciferase reporter gene assay2012European journal of medicinal chemistry, Dec, Volume: 58Fibrate-derived N-(methylsulfonyl)amides with antagonistic properties on PPARα.
AID624618Specific activity of expressed human recombinant UGT2B42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID326599Agonist activity at mouse PPARalpha receptor in monkey COS7 cells assessed as activation of CAT reporter gene at 150 uM by transactivation assay relative to Wy,14-6432008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Stereospecific synthesis and bio-activity of novel beta(3)-adrenoceptor agonists and inverse agonists.
AID156601Compound was tested for agonist activity on human Peroxisome proliferator activated receptor delta-GAL4 chimeric receptor in transfected CV-1 cells; IA = Inactive1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.
AID92236Inhibition of adenosine diphosphate (ADP) induced human platelet aggregation1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Synthetic aci-reductones: 3,4-dihydroxy-2H-1-benzopyran-2-ones and their cis- and trans-4a,5,6,7,8,8a-hexahydro diastereomers. Antiaggregatory, antilipidemic, and redox properties compared to those of the 4-substituted 2-hydroxytetronic acids.
AID92838Compound was tested for the inhibitory activity against serotonin secretion by adenosine -Diphosphate (ADP (1-5 uM))1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Comparative antiaggregatory activity in human platelets of a benzopyranone aci-reductone, clofibric acid, and a 2,3-dihydrobenzofuran analogue.
AID179924Inhibition against chloride conductance in rat extensor digitorum longus(EDL) muscle fibers in vitro1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Dissociation of hypolipidemic and antiplatelet actions from adverse myotonic effects of clofibric acid related enantiomers.
AID156231In vitro transcriptional activation of peroxisome proliferator activated alpha-receptor (PPAR) expressed in CV-1 cells1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones.
AID156453Compound was tested for its agonist activity against murine Peroxisome proliferator activated receptor alpha-Gal4 chimeric receptor transfected CV-1 cells1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.
AID92834Compound was tested for the inhibitory activity against human platelet aggregation by adenosine -Diphosphate (ADP (1-5 uM))1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Comparative antiaggregatory activity in human platelets of a benzopyranone aci-reductone, clofibric acid, and a 2,3-dihydrobenzofuran analogue.
AID91207Antigelling activity expressed as ratio of soluble sickle hemoglobin (HbS) of compound (g/dL) and that of control at 10 mM concentration1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Design, synthesis, and testing of potential antisickling agents. 10. (2,2-Dimethylchroman-6-yl)alkanoic acids.
AID1221780Cytotoxicity against HEK293 cells expressing UGT1A4 assessed as decrease in cell viability at 1 mM measured at 24 hrs by MTT assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID92837Compound was tested for the inhibitory activity against serotonin secretion by U-46,619 (0.3 uM) + Aspirin (ASA, 1 mM).1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Comparative antiaggregatory activity in human platelets of a benzopyranone aci-reductone, clofibric acid, and a 2,3-dihydrobenzofuran analogue.
AID1576351Thermodynamic solubility of compound in buffer containing KH2PO4/Na2HPO4 with 1% v/v DMSO at pH 6.8 incubated for 24 hrs by spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID92836Compound was tested for the inhibitory activity against human platelet aggregation by U46,619 (0.3 uM) + Aspirin (ASA, 1 mM).1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Comparative antiaggregatory activity in human platelets of a benzopyranone aci-reductone, clofibric acid, and a 2,3-dihydrobenzofuran analogue.
AID1221799Genotoxicity in HEK293 cells expressing UGT1A3 assessed as DNA strand breaks at 1 mM after 24 hrs by comet assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID91212Antigelling activity expressed as ratio of soluble sickle hemoglobin (HbS) of compound (g/dL) and that of control at 40 mM concentration.1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Design, synthesis, and testing of potential antisickling agents. 10. (2,2-Dimethylchroman-6-yl)alkanoic acids.
AID624615Specific activity of expressed human recombinant UGT2B102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1576349Octanol/water partition coefficient, logP of compound by RP-UHPLC analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID156786Compound was tested for its agonist activity against murine Peroxisome proliferator activated receptor delta-GAL4 chimeric receptor in transfected CV-1 cells; IA = Inactive1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.
AID609348Agonist activity at PPARalpha ligand binding domain expressed in HEK293 cells co-expressing GAL4 at 150 uM after 18 hrs by dual-luciferase activity based transactivation assay relative to control2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Benzothiazole-based N-(phenylsulfonyl)amides as a novel family of PPARα antagonists.
AID92240Inhibition of arachidonic acid (AA) induced serotonin secretion1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Synthetic aci-reductones: 3,4-dihydroxy-2H-1-benzopyran-2-ones and their cis- and trans-4a,5,6,7,8,8a-hexahydro diastereomers. Antiaggregatory, antilipidemic, and redox properties compared to those of the 4-substituted 2-hydroxytetronic acids.
AID22012Solubility ratio ([HbS+drug (10 mM)]/[HbS-drug])1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
AID157282Displacement of [3H]-BRL 49653 from glutathione S-transferase-Peroxisome proliferator activated receptor gamma ligand binding domain in bacterial extracts1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones.
AID693455Antagonist activity at PPARalpha expressed in HEK293A cells co-expressing GAL4 assessed as inhibition of GW7647-induced transactivation activity at 1 to 150 uM after 16 to 18 hrs by luciferase reporter gene assay2012European journal of medicinal chemistry, Dec, Volume: 58Fibrate-derived N-(methylsulfonyl)amides with antagonistic properties on PPARα.
AID1221821Cytotoxicity against HEK293 cells expressing UGT1A3 assessed as decrease in cell viability at 1 mM measured at 24 hrs by MTT assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID1576353Apparent solubility of compound in fasted state simulated intestinal fluid at pH 6.5 by spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1801103Fluorophore Displacement Assay from Article 10.1021/cb5005178: \\Characterization of two distinct modes of drug binding to human intestinal fatty acid binding protein.\\2014ACS chemical biology, Nov-21, Volume: 9, Issue:11
Characterization of two distinct modes of drug binding to human intestinal fatty acid binding protein.
AID1798916Cell-Based Transcription Assay from Article 10.1021/jm058056x: \\Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.\\2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,346)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990312 (23.18)18.7374
1990's343 (25.48)18.2507
2000's527 (39.15)29.6817
2010's149 (11.07)24.3611
2020's15 (1.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.76 (24.57)
Research Supply Index7.33 (2.92)
Research Growth Index4.43 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials103 (7.21%)5.53%
Reviews223 (15.61%)6.00%
Case Studies39 (2.73%)4.05%
Observational0 (0.00%)0.25%
Other1,064 (74.46%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effects on GLUcose Homeostasis of Changes in Plasma Lipoproteins Induced by Nutritional and Pharmacologic STrategies Against Diabetes-Related Metabolic Diseases [NCT05213988]50 participants (Anticipated)Interventional2018-07-30Enrolling by invitation
The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM) [NCT01527318]Phase 46 participants (Actual)Interventional2011-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]